Overview
BAYZED HEALTH (2609)
Bayzed Health Group Inc operates and manages a network of hospitals that provides oncology medical and healthcare services in the People’s Republic of China. Th...
- Open
- 2.410
- High
- 2.430
- Low
- 2.365
- Prev. Close
- 2.405
- Volume
- 1.76M
- Turnover
- 4.22M
- Avg Price
- 2.398
- Bid/Ask Ratio
- -97.44%
- Amplitude
- 2.70%
- 52wk High
- 7.040
- Volume Ratio
- 0.58
- Turnover Ratio
- 0.13%
- 52wk Low
- 2.365
- HK Mkt Cap
- 3.16B
- Market CapHKD
- 3.16B
- P/ETTM
- 94.51
- P/EDynamic
- 95.31
- P/EStatic
- --
- EPSTTM
- 0.0254
- EPSDynamic
- 0.0252
- EPSStatic
- --
- BVPS
- 1.33
- P/B
- 1.81
- HK Shares
- 1.32B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.32B
- Min lot size
- 600
- Currency
- HKD
Daily Events
- Nov, 9
Bayzed Health reversed early gains, opening at HK$2.740 at the session high before sliding to HK$2.555 by 15:46 BJ and closing at HK$2.615, down about 2.97% from the prior HK$2.695 close on HK$12.55 million turnover, extending a roughly 5% single-day decline in the previous session after shareholder Zhu Hongbing cut 1.8396 million shares at about HK$3.16. Interim results showed profit attributable to shareholders of HK$14.418 million against a year-earlier loss, with revenue of RMB584.45 million up only 1.7% and Q2 net profit up 155% year on year, yet a 2.47% net margin leaves the stock on 102.97x PE and 1.97x PB. The shares are down 32.78% year to date, 63.93% below the HK$7.25 52-week high and just 3.56% above the HK$2.525 low set on November 2, trading beneath both the MA20 of 2.704 and MA60 of 2.882, though a 0.36% turnover rate points to limited broad capitulation.
- Nov, 3
Bayzed Health rebounded off its low but still closed down 1.87% at HK$2.63, weighed by a shareholder sell-down: Zhu Hongbing cut 1.8396 million shares at about HK$3.16. It opened at HK$2.65, printed an intraday high of HK$2.66 in the morning session, then slid to HK$2.525 at 14:57 BJ, close to its 52-week low, before recovering to HK$2.63 on 4.38 million shares worth HK$11.42 million. Interim fundamentals ran the other way: first-half revenue rose 1.7% to RMB 584.45 million, profit attributable to shareholders of RMB 18.47 million marked a swing back into profit, and adjusted profit rose 96.8%; second-quarter net profit was HK$8.33 million, up 155% year on year. Against that, valuation and price position remain weak: 103.56x PE and 1.98x PB, with the price below both the MA20 of HK$2.763 and the MA60 of HK$2.904, down 32.39% year to date and 64.27% below the HK$7.36 52-week high. Though turnover of just 0.33% suggests supply at the lows was only partly absorbed.
- Oct, 27
Bayzed Health staged an intraday rebound, sliding to a 2.635 low at 10:54 before grinding back to close at the 2.700 session high, up 0.37% from the prior 2.690 close. The resilience tracks the interim turnaround: H1 net profit attributable reached RMB 18.47 million with adjusted profit up 96.8% year on year, while Q2 revenue came in at HKD 337.5 million, up 7.19%. Yet the price still sits below its MA20 of 2.83 and MA60 of 2.937, down 30.59% year to date, 70.3% below the 52-week high of 9.09 set on 16 October 2025 and only 5.26% above the 2.565 low of 21 October. Reductions by Zhu Hongbing of 1.8396 million shares near HKD 3.16 and by Shanghai Xukun of 5 million shares near HKD 2.95 cap the upside, though a 106x PE and 2.03x PB suggest elevated expectations are already priced in.
- Oct, 22
Bayzed Health closed down 1.1% at HK$2.69 on 3.82 million shares worth about HK$10.18 million, weighed by a run of shareholder disposals: Zhu Hongbing cut 1.8396 million shares near HK$3.16 and Shanghai Xukun trimmed 5 million shares near HK$2.95. The session traced a dip-and-recover shape, spiking to HK$2.755 at 10:18 BJ before sliding to HK$2.565 at 15:39 BJ, a fresh 52-week low, then clawing back to HK$2.69 into the close. Fundamentals and price diverge, with interim revenue up 1.7% to RMB 584.45 million, a swing to RMB 18.47 million attributable profit and adjusted profit up 96.8%, while Q2 net profit jumped 155.02% year on year to HK$8.33 million; yet the PE stands at 105.93x and the stock is down 30.85% year-to-date, 70.41% below its 52-week high of HK$9.09 and beneath both its MA20 of HK$2.856 and MA60 of HK$2.949. Turnover was just 0.29%, though, so thin liquidity can amplify moves.
- Oct, 15
Pressured by shareholder selldowns, Bayzed Health (2609.HK) spiked and faded through the Hong Kong morning before steadying late, closing at HK$2.650 after an intraday high of HK$2.765 at 10:17 and a low of HK$2.620 at 14:09, the latter matching its 52-week trough. Zhu Hongbing cut 1.8396 million shares at about HK$3.16 and Shanghai Xukun trimmed 5 million shares near HK$2.95, both above the current price. Fundamentals moved the other way: Q2 revenue of HK$337.5 million rose 7.19% year on year, net profit of HK$8.33 million climbed 155%, operating profit grew more than 34-fold and the interim result swung to profit, yet at roughly 105x PE the shares are down 31.23% year to date, below the MA20 of 2.906 and MA60 of 2.964. Turnover was thin though, at only HK$7.73 million with a 0.21% turnover rate.
